Generic drugmakers still face the threat of liability over a routine product labeling practice frequently under fire by brand-name companies despite a recent courtroom victory for Hikma Pharmaceuticals Plc. Drugmakers were relieved when a district court dismissed claims that Hikma was promoting use of a copycat version of Amarin’s Vascepa […]